Differences in guideline recommendations over time have impacted the views and use of PSA testing among PCPs.29 In our sample, PCPs consistently reported low confidence in PSA testing in reducing prostate cancer death and lack of familiarity with the 2 prospective screening trials that assessed the efficacy of PSA testing. The gene discussed is KLK3; the disease is Familial prostate cancer.